Higher offer secures Astellas's $4 billion acquisition of OSI
This article was originally published in Scrip
Executive Summary
Astellas has entered into a definitive agreement to acquire OSI Pharmaceuticals after raising its offer price to $57.50 per share, valuing the all-cash deal at around $4 billion on a fully diluted basis.